Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Today's Bonus Article
The Cannabis Sector's Billion-Dollar Tax CutBy Jeffrey Neal Johnson. Published: 4/23/2026. 
Key Points
- A major administrative policy shift is normalizing the tax structure for the cannabis industry, directly enhancing the financial standing of licensed operators.
- The largest multi-state operators are now positioned to leverage their significant revenues to generate substantial free cash flow for growth and expansion.
- This financial normalization shifts the investment focus from speculative policy hopes toward the tangible business fundamentals of established market leaders.
- Special Report: Have $500? Invest in Elon’s AI Masterplan
On the heels of the executive order to fast-track research into psychedelic drugs, a second major federal policy shift on April 23, 2026, is reverberating through the cannabis sector. But many on Wall Street are misreading the real catalyst. The administration’s decision to move state-licensed medical marijuana from Schedule I to Schedule III of the Controlled Substances Act is not federal legalization. Rather, it’s a surgical change buried in the U.S. tax code that could unlock billions in value for a select group of companies. For investors, the shift moves the conversation from speculative policy hopes to tangible cash-flow dynamics, and it creates a clearer playbook for identifying which cannabis companies can become profitable. How the Death of 280E Changes Everything
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itself - it's the infrastructure behind it.
One small-cap company supplies a mission-critical component to Musk's xAI Colossus site that can't be built around. While retail waits for a ticker that doesn't exist yet, early money is moving into this supplier at a fraction of its potential value. See the small-cap stock powering the SpaceX buildout today
For more than a decade, U.S. cannabis businesses have been uniquely burdened by Internal Revenue Code Section 280E. Designed in the 1980s to stop illegal drug traffickers from claiming business deductions, 280E was applied to state-legal cannabis companies. In practice, licensed operators were denied ordinary business deductions — things like rent, payroll, and marketing — and were taxed on gross profits rather than net income. That distortion produced crushing effective tax rates that often exceeded 70%. The administrative reclassification to Schedule III effectively removes 280E for state-licensed medical operators. That change lets these companies be taxed like other businesses, reducing their effective federal tax rate toward the statutory corporate rate of roughly 21%. The valuation impact is immediate and material. This policy shift acts like a large, non-dilutive boost to cash flow: net income and earnings per share should improve, and management teams will suddenly have hundreds of millions of dollars available to invest in growth, pay down debt, or return capital to shareholders instead of sending it to the IRS. The New Kings of Cannabis Cash FlowAlthough the whole sector benefits in theory, the biggest financial winners are clear: leading U.S. Multi-State Operators (MSOs) with scale, diversified revenue streams, and established operating infrastructures. These companies are best positioned to convert tax savings into durable profits. The Profitability KingGreen Thumb Industries (OTCMKTS: GTBIF) stands out. It was one of the few major MSOs to generate consistent net income even while carrying the full weight of 280E, reporting trailing net income of $114.15 million. With a price-to-earnings ratio near 15x before the policy change, Green Thumb’s profitability is poised to expand substantially. The additional cash flow could be deployed to further market its consumer brands, such as Rythm and Dogwalkers, and to accelerate share gains in key states. The Scale and Shareholder-Return PlayWith roughly $1.27 billion in annual sales, Curaleaf (OTCMKTS: CURLF) has the scale to realize some of the largest absolute tax savings in the industry. The company underscored its confidence by launching an $83 million share buyback program. A buyback is a classic sign of a company with surplus cash and a priority on returning value to shareholders. Announcing that program days before the policy shift may signal management’s belief that meaningful capital will be freed up once 280E no longer applies to licensed medical operations. The High-Leverage and Strategic Plays: Trulieve, Verano, and Cresco LabsOther MSOs are positioned to funnel tax savings into growth. Trulieve Cannabis (OTCMKTS: TCNNF), with dominant market share in Florida and strong political ties, could use the extra cash to fortify its position ahead of a potential adult-use ballot measure. Cresco Labs (OTCMKTS: CRLBF), which recently secured a medical license in Texas, and Verano Holdings (OTCMKTS: VRNOF), which streamlined its structure by redomiciling to Nevada, now have more flexibility to fund expansion without excessive borrowing or shareholder dilution. The Tilray Contrast: Know What You OwnWhen cannabis headlines break, many investors gravitate toward familiar, NASDAQ-listed names like Tilray Brands, Inc. (NASDAQ: TLRY), preferring perceived liquidity and exchange-listed disclosure standards over over-the-counter tickers. But Tilray’s business model is much more focused on the Canadian adult-use market, international medical markets and its consumer beverage brands like SweetWater Brewing. It is not a U.S. plant-touching operator and therefore was not subject to the punitive U.S. 280E tax. As a result, Tilray does not receive the direct financial lift from this particular policy change and is better viewed as a sympathy trade than a primary beneficiary. The Green Wave: A New Era for Cannabis ProfitsMoving medical marijuana to Schedule III is a partial — but potentially historic — win for the U.S. cannabis industry. It does not legalize cannabis federally, permit interstate commerce, or automatically clear the path for listings on major U.S. exchanges. Those remain meaningful constraints investors should watch. Still, by normalizing the tax treatment for licensed medical operators, the change gives the strongest U.S. MSOs the chance to build financial fortresses. The urgency for federal banking reform remains, but it becomes less critical now that MSOs can generate internal cash flow to fund operations and growth. The investment playbook has shifted. The smart strategy is less about betting on sweeping policy reform and more about identifying U.S. MSOs that can convert these substantial tax savings into sustainable earnings and shareholder returns. While the industry hasn’t received full federal legalization, it has received an important financial green light. Investors interested in the space should consider adding top U.S. MSOs to their watchlists and watch upcoming quarterly reports closely for management’s first formal guidance in the post-280E environment. |
Post a Comment
0Comments